SIBO, Honestly: What the Science Actually Supports

SIBO is a real diagnosis, and that's where the honesty has to start

Small intestinal bacterial overgrowth is what its name says: too many bacteria in the small intestine, producing gastrointestinal symptoms. The American College of Gastroenterology published a clinical guideline on it in 2020 that defines it that way, examines how breath testing performs as a diagnostic method, and issues a conditional recommendation to treat symptomatic SIBO with antibiotics 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the recognised limitations of breath-test diagnosis, and the conditional nature of the recommendation to treat symptomatic SIBO with antibiotics.. This is not a fringe idea being smuggled in from the margins. It is a guideline-level condition in mainstream gastroenterology.

Small intestinal bacterial overgrowth (SIBO) is an excess of bacteria in the small intestine sufficient to cause gastrointestinal symptoms 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the recognised limitations of breath-test diagnosis, and the conditional nature of the recommendation to treat symptomatic SIBO with antibiotics..

Starting there matters, because the public argument about SIBO almost always opens in the wrong place. One camp treats it as the hidden cause of nearly every chronic digestive complaint. The other treats it as pseudoscience invented to sell breath tests and supplements. Neither of those is what the guideline says, and both leave the person with the actual bloated abdomen worse off than before they read anything.

The useful question is not whether SIBO exists. It does. The useful question is narrower, and much less satisfying: in one specific person with bloating and unpredictable bowels, how confidently can anyone say this is the thing they have — and how much does saying so change what helps them? That question has an honest answer. The honest answer is: less confidently than the diagnosis is usually delivered.

One structural fact drives everything that follows. The small intestine is not sterile. Bacteria belong there. "Overgrowth" is therefore a quantitative claim about a population that is supposed to be present — and a condition defined by too much of a normal thing lives or dies on having a reliable way to measure how much. That measurement is the part that has never been settled.

Where the science stops: the breath test

The ACG guideline addresses breath-test diagnosis of SIBO and states plainly that the method carries limitations 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the recognised limitations of breath-test diagnosis, and the conditional nature of the recommendation to treat symptomatic SIBO with antibiotics.. That sentence deserves far more weight than it usually receives, because in practice the breath test is not one input among several that a clinician weighs. For most people who receive a SIBO diagnosis, the breath test is the entire basis of it. When the sole instrument has acknowledged limitations, those limitations are not a technical footnote — they are the diagnosis.

The shape of the problem is worth understanding, because it explains why sensible people disagree. The test works by having you swallow a sugar and then measuring gases in your exhaled breath. The reasoning is that bacteria in the small intestine will ferment that sugar early and produce a rise in gas that shows up in your breath sooner than it otherwise would. But the large intestine is densely populated with bacteria that ferment the very same sugar. So the difference between "bacteria fermented this in the small bowel" and "the sugar simply reached the colon faster than the test assumes" is not observed. It is inferred, from timing.

A breath test result is an inference from timing, not a photograph of the small intestine. That is why two clinicians can read the same result and disagree about whether the person in front of them has SIBO.

Those sibo breath test limits are the reason this page exists in the form it does. A test that cannot cleanly separate the condition from ordinary variation in how fast food moves will label some people who do not have the condition. That is not a scandal — it is a known property of an imperfect method, and the guideline says so 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the recognised limitations of breath-test diagnosis, and the conditional nature of the recommendation to treat symptomatic SIBO with antibiotics.. The scandal, where there is one, is in how the result gets delivered: as a fact, in a number, with a protocol attached.

Why "overdiagnosis" is the right word for what happens next

There is a formal name for finding something that was never going to be the problem, and a formal literature behind it. It was worked out most rigorously in cancer screening, where overdiagnosis means detecting, through screening, a cancer that would never have caused symptoms or death in that person's lifetime. It is counted as a harm of screening rather than a benefit, because it delivers treatment to someone who could not have benefited from it 2Ref 2Welch HG, Black WC (2010).Overdiagnosis in cancer.The definition of overdiagnosis in cancer screening — detecting disease that would never have caused symptoms or death — and the reason it counts as a harm of testing, cited explicitly as the cancer-screening concept from which the reasoning is borrowed..

SIBO is not cancer, and that definition is a cancer-screening definition. What transfers is not the disease but the shape of the reasoning. Apply an imperfect test broadly to a population of people with common, non-specific symptoms, and it will return positives. Attach a label to those positives and treatment follows the label — because that is what labels do. Nobody in that chain acts in bad faith, and the harm still occurs.

The reason overdiagnosis is so hard to see from the inside is that it does not feel like harm. It feels like an answer. After years of being told nothing is wrong, a positive test is a profound relief: it is proof you were not imagining it, a name for the thing, and a plan. That relief is real, and it is not something to be sneered at. It is also exactly what makes the label stick regardless of whether it was the right one.

And the cost is genuine, even when the treatment is harmless. A wrong frame consumes the thing you have least of — time, money, and the willingness to keep looking. Someone eighteen months into rounds of testing and protocols for SIBO is eighteen months from the appointment where somebody asks a different question.

SIBO and IBS overlap so much that the label may be the main difference

The symptoms attributed to SIBO — bloating, distension, abdominal pain, loose or irregular stools — are the symptoms of irritable bowel syndrome. This is not a coincidence or a diagnostic subtlety. It is the central fact, and any honest account of SIBO has to sit with it rather than route around it.

IBS itself was reframed in the Rome IV criteria, which recast the functional gastrointestinal disorders as disorders of gut-brain interaction and revised the IBS definition around abdominal pain related to defecation 3Ref 3Schmulson MJ, Drossman DA (2017).What Is New in Rome IV.That Rome IV reframed the functional gastrointestinal disorders as disorders of gut-brain interaction and revised the IBS definition around abdominal pain related to defecation.. That reframing is not a downgrade and it does not mean the symptoms are imagined. It is a statement about mechanism: the communication between gut and brain is where the disorder lives, and that is a physical system, not a figure of speech.

A disorder of gut-brain interaction is a condition arising from the signalling between the gut and the nervous system, rather than from visible structural damage 3Ref 3Schmulson MJ, Drossman DA (2017).What Is New in Rome IV.That Rome IV reframed the functional gastrointestinal disorders as disorders of gut-brain interaction and revised the IBS definition around abdominal pain related to defecation..

The AGA's clinical practice update on bloating and distension lands in the same territory: bloating is frequently associated with IBS and other disorders of gut-brain interaction, and its management may involve dietary change, brain-gut behavioural therapies, and neuromodulators 4Ref 4Moshiree B, Drossman D, Shaukat A (2023).AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review.That bloating is frequently associated with IBS and other disorders of gut-brain interaction, and that its management may include dietary change, brain-gut behavioural therapies, and neuromodulators.. Read that list against the SIBO protocols sold online and the gap is striking — one of these accounts of chronic bloating has a guideline behind it, and it is not the one with the supplement schedule.

So the question of ibs versus sibo may be less a question about two conditions than about which name got applied to one presentation, by whom, and with what attached. Is it ibs or sibo is worth asking out loud at the appointment, because the two names lead to different rooms — and only one of the two has brain-gut behavioural therapy and neuromodulators in its toolkit 4Ref 4Moshiree B, Drossman D, Shaukat A (2023).AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review.That bloating is frequently associated with IBS and other disorders of gut-brain interaction, and that its management may include dietary change, brain-gut behavioural therapies, and neuromodulators..

What rifaximin has actually been shown to do

The antibiotic most associated with SIBO is rifaximin — and the trial most often invoked on its behalf did not study SIBO. The TARGET 1 and TARGET 2 phase 3 randomised trials tested two weeks of rifaximin against placebo in patients with irritable bowel syndrome without constipation, and found modest but statistically significant relief of global symptoms and of bloating 5Ref 5Pimentel M, Lembo A, Chey WD, et al. (TARGET Study Group) (2011).Rifaximin therapy for patients with irritable bowel syndrome without constipation.That the phase 3 TARGET 1 and 2 trials tested a two-week course of rifaximin against placebo in IBS without constipation and found modest but significant relief of global symptoms and bloating, and that the trials did not cover IBS with constipation.. That is a genuine result from a genuine trial. It is a result about IBS.

Set that beside what the SIBO guideline itself says. The ACG's recommendation to treat symptomatic SIBO with antibiotics is conditional 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the recognised limitations of breath-test diagnosis, and the conditional nature of the recommendation to treat symptomatic SIBO with antibiotics., and in guideline language that word is not a rhetorical softener. A conditional recommendation means the panel judged the evidence insufficient to compel the action for everyone, and that well-informed people looking at the same evidence would reasonably choose differently.

Put those two facts side by side and the picture is genuinely odd: the strongest trial evidence connected to this drug sits in a neighbouring condition, while the recommendation in the condition itself is conditional. So does rifaximin work for sibo is a question the famous trial does not answer, even though it is the trial most often produced when someone asks. Rifaximin for sibo is a reasonable thing to discuss with a gastroenterologist. It is not a settled matter being withheld from you.

Two further details of the TARGET result are routinely lost in the retelling. It was not a cure — "modest but significant" is the accurate description of the effect size, and it came from a defined course rather than an open-ended one. And it did not cover IBS with constipation 5Ref 5Pimentel M, Lembo A, Chey WD, et al. (TARGET Study Group) (2011).Rifaximin therapy for patients with irritable bowel syndrome without constipation.That the phase 3 TARGET 1 and 2 trials tested a two-week course of rifaximin against placebo in IBS without constipation and found modest but significant relief of global symptoms and bloating, and that the trials did not cover IBS with constipation., which is precisely the group most likely to be handed the methane-predominant version of a SIBO diagnosis.

Diet: what the FODMAP evidence supports, and what it doesn't

The dietary approach with the most standing here was not built for SIBO either. FODMAPs are fermentable oligosaccharides, disaccharides, monosaccharides and polyols — short-chain carbohydrates that bacteria ferment readily — and Monash University, where the approach was developed, reports that a low FODMAP diet improves symptoms in roughly three in four people with IBS 6Ref 6Monash University, Department of Gastroenterology (2024).About FODMAPs and IBS.The definition of FODMAPs as fermentable oligo-, di-, monosaccharides and polyols, and the originating institution's report that a low FODMAP diet improves symptoms in roughly three in four people with IBS — flagged in-text as a developer-reported figure rather than independent efficacy data..

The originating institution reports that a low FODMAP diet improves symptoms in roughly 3 in 4 people with IBS 6Ref 6Monash University, Department of Gastroenterology (2024).About FODMAPs and IBS.The definition of FODMAPs as fermentable oligo-, di-, monosaccharides and polyols, and the originating institution's report that a low FODMAP diet improves symptoms in roughly three in four people with IBS — flagged in-text as a developer-reported figure rather than independent efficacy data. — a figure from the group that developed it, and not a substitute for independent peer-reviewed efficacy data.

That caveat is not a technicality, and it is worth saying out loud on a page about evidence honesty: a developer reporting on its own intervention is a source with an interest. The figure is still the best plain-language statement of the diet's reach, and it should be read as what it is.

What the low-fodmap diet is not is a SIBO treatment with SIBO evidence. It is an IBS intervention, and it overlaps with SIBO protocols because the symptoms overlap. It is also not a permanent way of eating — the low fodmap diet three phases structure exists because the restriction phase is a diagnostic manoeuvre, not a destination, and the phases that follow are where the actual answer for a given person is found. Restriction that never ends is a common failure of this diet in the wild, and it narrows a person's food to no purpose.

The AGA's bloating update puts dietary change in the company of brain-gut behavioural therapies and neuromodulators 4Ref 4Moshiree B, Drossman D, Shaukat A (2023).AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review.That bloating is frequently associated with IBS and other disorders of gut-brain interaction, and that its management may include dietary change, brain-gut behavioural therapies, and neuromodulators. — which is to say, as one lever among several rather than the whole apparatus. That framing is more useful than any single protocol, because it treats chronic bloating as something with multiple entry points instead of one hidden cause waiting to be eradicated.

Why it keeps coming back

Recurrence is the most common experience people report after SIBO treatment, and it is where the two readings of this condition diverge most sharply. One reading: the overgrowth was real, the antibiotic cleared it, and whatever allowed it to develop is still there, so it returned. The other reading: what was being treated was a chronic disorder of gut-brain interaction all along, an antibiotic transiently changed the symptoms, and their return is not a relapse of an infection but the underlying condition simply continuing.

Both readings predict the identical experience — feeling better, then feeling worse again a few months later. That is the difficulty. The pattern that people take as confirmation of the SIBO frame is equally consistent with the frame being wrong, and no amount of repeating the breath test resolves the ambiguity, because it is the same imperfect inference each time 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the recognised limitations of breath-test diagnosis, and the conditional nature of the recommendation to treat symptomatic SIBO with antibiotics..

This page cannot tell you which reading applies to you, and anyone who tells you confidently, from a distance, without knowing you, is telling you something they do not know. Why sibo keeps coming back is a real question with a genuinely contested answer, and sibo recurrence is the point at which it is most worth pausing to ask whether the frame itself should be re-examined — rather than simply running the protocol again, harder.

A related label deserves a mention because it is where constipation-predominant symptoms usually get routed. Methane sibo (imo) — intestinal methanogen overgrowth — is the name applied when methane rather than hydrogen dominates the breath result and constipation rather than diarrhoea dominates the symptoms. It is worth knowing the term exists, and worth knowing that the trial evidence discussed above explicitly did not cover IBS with constipation 5Ref 5Pimentel M, Lembo A, Chey WD, et al. (TARGET Study Group) (2011).Rifaximin therapy for patients with irritable bowel syndrome without constipation.That the phase 3 TARGET 1 and 2 trials tested a two-week course of rifaximin against placebo in IBS without constipation and found modest but significant relief of global symptoms and bloating, and that the trials did not cover IBS with constipation..

How to hold a SIBO diagnosis honestly

None of this adds up to "ignore the diagnosis." It adds up to holding it more loosely than it was probably handed to you, and asking a specific set of questions rather than accepting the label as a settled fact. The condition is real 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the recognised limitations of breath-test diagnosis, and the conditional nature of the recommendation to treat symptomatic SIBO with antibiotics.; the confidence attached to any individual diagnosis of it is the part that deserves scrutiny.

Questions that tend to be worth raising with the clinician who made the diagnosis:

• What else was excluded before this label was applied? SIBO is often the first name a person is given for chronic bloating rather than the last, and the conditions with definite tests are the ones worth settling first.
• What would change if this were IBS instead? If the answer is "nothing," the label is doing less work than it appears to. If the answer includes brain-gut behavioural therapy or a neuromodulator 4Ref 4Moshiree B, Drossman D, Shaukat A (2023).AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review.That bloating is frequently associated with IBS and other disorders of gut-brain interaction, and that its management may include dietary change, brain-gut behavioural therapies, and neuromodulators., the label is actively costing you options.
• What does a repeat breath test add? Given the method's acknowledged limitations 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the recognised limitations of breath-test diagnosis, and the conditional nature of the recommendation to treat symptomatic SIBO with antibiotics., a second run of the same inference may not settle anything the first one didn't.
• Is what's being recommended inside the guideline or outside it? The ACG's recommendation, such as it is, is a conditional one for antibiotics 1Ref 1Pimentel M, Saad RJ, Long MD, Rao SSC (2020).ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.The definition of SIBO as excessive small-bowel bacteria causing GI symptoms, the recognised limitations of breath-test diagnosis, and the conditional nature of the recommendation to treat symptomatic SIBO with antibiotics.. What sits outside that is outside what has been assessed — which is a statement about the evidence base, not a verdict on any individual therapy.

If you have been given a SIBO diagnosis, you have not been lied to and you have not wasted your time. The symptoms are real, they have been taken seriously enough to test for, and a contested label is still a place to start from — as long as it stays open to being revised.